These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 15772959)
41. C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study. Nakopoulou L; Stefanaki K; Filaktopoulos D; Giannopoulou I Histol Histopathol; 1994 Oct; 9(4):677-82. PubMed ID: 7894139 [TBL] [Abstract][Full Text] [Related]
42. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Buchholz TA; Tu X; Ang KK; Esteva FJ; Kuerer HM; Pusztai L; Cristofanilli M; Singletary SE; Hortobagyi GN; Sahin AA Cancer; 2005 Aug; 104(4):676-81. PubMed ID: 15981280 [TBL] [Abstract][Full Text] [Related]
43. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900 [TBL] [Abstract][Full Text] [Related]
44. Biological markers and prognosis in recurrent oral cancer after salvage surgery. Agra IM; Carvalho AL; Pinto CA; Martins EP; Filho JG; Soares FA; Kowalski LP Arch Otolaryngol Head Neck Surg; 2008 Jul; 134(7):743-9. PubMed ID: 18645125 [TBL] [Abstract][Full Text] [Related]
45. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793 [TBL] [Abstract][Full Text] [Related]
46. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Foster J; Black J; LeVea C; Khoury T; Kuvshinoff B; Javle M; Gibbs JF Ann Surg Oncol; 2007 Feb; 14(2):752-8. PubMed ID: 17146741 [TBL] [Abstract][Full Text] [Related]
47. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012 [TBL] [Abstract][Full Text] [Related]
48. Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer. Fink-Retter A; Gschwantler-Kaulich D; Hudelist G; Mueller R; Kubista E; Czerwenka K; Singer CF Oncol Rep; 2007 Aug; 18(2):299-304. PubMed ID: 17611648 [TBL] [Abstract][Full Text] [Related]
49. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Matsubara J; Yamada Y; Nakajima TE; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T Oncology; 2008; 74(1-2):76-83. PubMed ID: 18544998 [TBL] [Abstract][Full Text] [Related]
50. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate. Mitsuhashi T; Nakayama M; Sakurai S; Fujimura M; Shimizu Y; Ban S; Ogawa F; Hirose T; Ishihara O; Shimizu M Ann Diagn Pathol; 2007 Feb; 11(1):49-54. PubMed ID: 17240308 [TBL] [Abstract][Full Text] [Related]
51. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y Surgery; 2003 Feb; 133(2):219-21. PubMed ID: 12605184 [TBL] [Abstract][Full Text] [Related]
52. A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process? Kara IO; Gonlusen G; Sahin B; Ergin M; Erdogan S Saudi Med J; 2005 Aug; 26(8):1190-6. PubMed ID: 16127511 [TBL] [Abstract][Full Text] [Related]